EU approves Gilead’s hepatitis B therapy Vemlidy
Patients with chronic hepatitis B in Europe have gained the first new treatment option in nearly 10 years following the approval of Gilead’s Vemlidy.
Read More
Tag: TAF
EU nod for Gilead’s single-pill HIV therapy
European regulators have granted marketing authorisation to Gilead’s Odefsey for the treatment of certain patients with HIV-1 infection.
Read More
